Abstract
Previous studies show that acetylsalicylic acid (aspirin) at low concentrations affects yeast sexual structure development in a similar fashion than oxygen depletion. This is ascribed to its anti-mitochondrial action. In this study, we report the same for other anti-inflammatory (i.e. ibuprofen, indomethacin, salicylic acid, benzoic acid) as well as anticancer (Lonidamine) drugs, also known for inhibiting mitochondrial activity in mammalian cells. This is shown by a unique yeast bio-assay, with the mitochondrion-dependent sexual structure, riboflavin production, and hyphal morphology of the yeast Eremothecium ashbyi serving as indicators. These drugs affect this yeast in a similar way as found under oxygen limitation conditions by inhibiting sexual structure development (most sensitive), riboflavin production, and yielding characteristically wrinkled and granular hyphae, presenting a unique “anoxic” morphological pattern for this yeast. Only drugs associated with anti-mitochondrial activity presented such a pattern. This bio-assay may find application in the screening for novel drugs from various sources with anti-mitochondrial actions.
Keywords: Anticancer, antifungal, anti-inflammatory, anti-mitochondrion, bio-assay, yeast
Current Drug Discovery Technologies
Title: Development of a Yeast Bio-Assay to Screen Anti-Mitochondrial Drugs
Volume: 6 Issue: 3
Author(s): Johan L.F. Kock, Chantel W. Swart, Desmond M. Ncango, Johan L.F. Kock Jr., Ingrid A. Munnik, Marleen M.J. Maartens, Carolina H. Pohl and Pieter W.J. van Wyk
Affiliation:
Keywords: Anticancer, antifungal, anti-inflammatory, anti-mitochondrion, bio-assay, yeast
Abstract: Previous studies show that acetylsalicylic acid (aspirin) at low concentrations affects yeast sexual structure development in a similar fashion than oxygen depletion. This is ascribed to its anti-mitochondrial action. In this study, we report the same for other anti-inflammatory (i.e. ibuprofen, indomethacin, salicylic acid, benzoic acid) as well as anticancer (Lonidamine) drugs, also known for inhibiting mitochondrial activity in mammalian cells. This is shown by a unique yeast bio-assay, with the mitochondrion-dependent sexual structure, riboflavin production, and hyphal morphology of the yeast Eremothecium ashbyi serving as indicators. These drugs affect this yeast in a similar way as found under oxygen limitation conditions by inhibiting sexual structure development (most sensitive), riboflavin production, and yielding characteristically wrinkled and granular hyphae, presenting a unique “anoxic” morphological pattern for this yeast. Only drugs associated with anti-mitochondrial activity presented such a pattern. This bio-assay may find application in the screening for novel drugs from various sources with anti-mitochondrial actions.
Export Options
About this article
Cite this article as:
Kock L.F. Johan, Swart W. Chantel, Ncango M. Desmond, Kock Jr. L.F. Johan, Munnik A. Ingrid, Maartens M.J. Marleen, Pohl H. Carolina and van Wyk W.J. Pieter, Development of a Yeast Bio-Assay to Screen Anti-Mitochondrial Drugs, Current Drug Discovery Technologies 2009; 6 (3) . https://dx.doi.org/10.2174/157016309789054960
DOI https://dx.doi.org/10.2174/157016309789054960 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quercetin as a Systemic Chemopreventative Agent: Structural and Functional Mechanisms
Mini-Reviews in Medicinal Chemistry Metal-Based Antioxidants - Potential Therapeutic Candidates for Prevention the Oxidative Stress - Related Carcinogenesis: Mini-Review
Current Topics in Medicinal Chemistry Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment
Current Medicinal Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry TAP-Independent MHC Class I Presentation
Current Immunology Reviews (Discontinued) Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Recent Patents on the Development of c-Met Kinase Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 4
Cardiovascular & Hematological Agents in Medicinal Chemistry Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
Current Pharmaceutical Design New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway
Current Pharmaceutical Design Anticancer Activity of the Bioreductive and Non-Bioreductive Zerumbone Derivatives
Letters in Drug Design & Discovery Design, Synthesis and Biological Evaluation of 2, 4, 5-Triphenylimidazole Derivatives with Preliminary SAR
Letters in Drug Design & Discovery Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Pharmacogenomics of COPD
Current Pharmacogenomics Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology